Inhibitors of carnitine palmitoyltransferase and treating cancer

A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof:

• Wherein
• R1 is —OH or —OC1-6 alkyl;
• R3 is —N(R7R8) or —N±(R7R8R9)X−;
• each of R7, R8, R9 independently is —H or C1-6 alkyl;
• X− is a pharmaceutically acceptable counter ion;
• and
• a) Q is —C(═O)—, —C(═S)—, —C(O)NH—or —C(S)NH—;
• and
• R4 is a substituted aryl group, or a substituted or unsubstituted heteroaryl group, provided that when R4 is a substituted phenyl group, then R3 is —N±(R7R8R9)X−;
• or
• b) Q is —C(═NH)—, —S(O)—, —S(O)2—, —S(O)—NH—, or —S(O)2—NH—;
• and
• R4 is a substituted or unsubstituted aryl group, or substituted or unsubstituted heteroaryl group, provided that when Q is —S(O)2—, then R4 is not a tolyl group;
• or
• c) Q is —C(═O)—N(R5)—, —C(═S)—N(R5)—, —C(═NH)—N(R5)—, —S(O)—N(R5)— or —S(O)2—N(R5)—;
• and
• R4 and R5 are each independently a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, or R4 and R5 taken together with the nitrogen atom of N(R4R5) form a substituted or unsubstituted non-aromatic heterocyclic ring.